<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17 PATIENT COUNSELING INFORMATION<BR>               <BR>                  <BR>                     See FDA-approved patient labeling (17.2).<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1 Information for Patients<BR>                     <BR>                        Patients should be informed of the following: <BR>                        <BR>                           <BR>                              •TYKERB has been reported to decrease left ventricular ejection fraction which may result in shortness of breath, palpitations, and/or fatigue. Patients should inform their physician if they develop these symptoms while taking TYKERB.<BR>                           <BR>                              •TYKERB often causes diarrhea which may be severe in some cases. Patients should be told how to manage and/or prevent diarrhea and to inform their physician immediately if there is any change in bowel patterns or severe diarrhea occurs during treatment with TYKERB. <BR>                           <BR>                              •TYKERB may interact with many drugs; therefore, patients should be advised to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products. <BR>                           <BR>                              •TYKERB may interact with grapefruit. Patients should not take TYKERB with grapefruit products.<BR>                           <BR>                              •TYKERB should be taken at least one hour before or one hour after a meal, in contrast to capecitabine which should be taken with food or within 30 minutes after food.<BR>                           <BR>                              •The dose of TYKERB should be taken once daily. Dividing the daily dose is not recommended.<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.2 FDA-Approved Patient Labeling<BR>                     <BR>                        Patient labeling is provided as a tear-off leaflet at the end of this full prescribing information. <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>